MannKind Corporation
NASDAQ:MNKDBiotechnology
-$0.02 today
- Market cap
- $1.31B
- Beta
- 1.11
- P/E (TTM)
- -50.3
- EPS (TTM)
- -$0.08
Volume 2.12M
Average 5.73M
MNKD Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
MannKind CorporationNASDAQ: MNKD
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $21.84M rose 24.7% year over year, ahead of the +14.8% change in trailing-twelve-month cost of revenue. Sequentially, it fell 9.5% from the prior quarter. Over 3 fiscal years it compounded at +2.1% a year.
Context
- Cost of revenue amounted to 17.5% of revenue in FY2025, down 9.3 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +24.7% holds above the trailing-twelve-month pace of +14.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 61.16M USD
- Year-over-year change
- -20.2%
- 4-year CAGR
- +12.0%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 61.16M | -20.2% |
| FY2024 | 2024-12-31 | 76.6M | +22.0% |
| FY2023 | 2023-12-31 | 62.77M | +9.2% |
| FY2022 | 2022-12-31 | 57.5M | +48.0% |
| FY2021 | 2021-12-31 | 38.86M | — |
Cost of Revenue vs competitors
How MNKD compares with its peers on the latest reported figures
- MNKD's LTM Mar 2026 cost of revenue of $86.73M is the highest of the 6 companies compared; the peer median is $21.55M.
- Its year-over-year change of +14.8% is the 4th highest of 6, against a peer median of +37.0%.
- Cost of revenue amounts to 24.0% of revenue for MNKD, versus a peer median of 21.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $86.73M | +14.8% | +2.1% | 24.0% | |
| LTM Mar 2026 | $57.97M | +37.0% | +33.1% | 18.4% | |
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | $22.66M | +51.6% | +6.1% | 22.9% |
| LTM Mar 2026 | $21.55M | -46.3% | -55.7% | 19.6% | |
| LTM Mar 2026 | $1.44M | +35950.0% | +401.7% | 62.9% | |
| LTM Mar 2026 | $31K | -98.5% | — | — | |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding MNKD) | $21.55M | +37.0% | +19.6% | 21.3% | |
Competitors are the stored peer set for MNKD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75.44M | 99.77M | 198.96M | 285.5M | 348.97M |
| Cost of Revenue | 38.86M | 57.5M | 62.77M | 76.6M | 61.16M |
| Gross Profit | 36.59M | 42.27M | 136.19M | 208.9M | 287.81M |
| Gross Margin | 48.5% | 42.4% | 68.5% | 73.2% | 82.5% |
| Research & Development | 12.31M | 19.72M | 31.28M | 45.89M | 66.35M |
| Selling, General & Admin | 77.42M | 91.47M | 94.31M | 94.33M | 144.14M |
| Operating Expenses | 83.61M | 106.38M | 127.51M | 136.32M | 249.01M |
| Depreciation & Amortization | 3.24M | 6.31M | 4.54M | 8.97M | 12.28M |
| EBITDA | (61.11M) | (56.32M) | 15.13M | 77.47M | 27.52M |
| EBITDA Margin | -81.0% | -56.4% | 7.6% | 27.1% | 7.9% |
| Operating Income | (47.02M) | (64.11M) | 8.68M | 72.59M | 38.8M |
| Operating Margin | -62.3% | -64.3% | 4.4% | 25.4% | 11.1% |
| Interest Income | 112K | 2.51M | 6.15M | 12.62M | 0 |
| Interest Expense | 16.58M | 24.77M | 25.16M | 37.98M | 13.83M |
| Other Income / Expenses | (33.9M) | (23.29M) | (19.06M) | (42.07M) | (37.39M) |
| Income Before Tax | (80.93M) | (87.4M) | (10.38M) | 30.52M | 1.41M |
| Pre-Tax Margin | -107.3% | -87.6% | -5.2% | 10.7% | 0.4% |
| Income Tax Expense | 0 | 0 | 1.56M | 2.93M | (4.46M) |
| Net Income | (80.93M) | (87.4M) | (11.94M) | 27.59M | 5.86M |
| Net Margin | -107.3% | -87.6% | -6.0% | 9.7% | 1.7% |
| EPS (Basic) | (0.37) | (0.44) | (0.04) | 0.10 | 0.02 |
| EPS (Diluted) | (0.37) | (0.44) | (0.04) | 0.10 | 0.02 |
| Weighted Avg Shares | 249.24M | 257.09M | 267.01M | 274.42M | 305.64M |
| Weighted Avg Shares (Diluted) | 249.24M | 257.09M | 267.01M | 283.84M | 314.11M |
MannKind Corporation
NASDAQ:MNKD
Intrinsic Alpha fair value
Locked
Current Price
$4.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.